Novotech
Novotech is recorded as a service provider in 33 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 33 trials · Latest update first
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
Sponsor Tectonic Therapeutic Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
Sponsor Elevara Medicines Limited
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease
Sponsor Arrowhead Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Enrollment spanned seven countries, with 42 of 62 participants enrolled in New Zealand.
- Participants remained in the study for at least 33 weeks and attended regular study-site visits.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma
Sponsor Immunocore Limited
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study randomized 378 patients at 58 sites in 14 countries.
- Tebentafusp required at least 16 hours of inpatient monitoring after dosing on Cycle 1 Days 1, 8, and 15 because of anticipated cytokine release syndrome.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
Sponsor Phenonet Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomised, Placebo-Controlled, Double-Blind, Single-Ascending Dose and Multiple-Ascending Dose First-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered ALE1 With or Without Food in Healthy Adult Participants and Adult Patients With Hypophosphatasia
Sponsor Alesta Therapeutics B.V.
- Start (EU)
- Latest update
- Estimated end
A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B
Sponsor Nchroma Bio Inc.
- Start (EU)
- Latest update
- Estimated end
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of PARP1-selective inhibitor, EIK1003 (IMP1734), as monotherapy and in combination in participants with advanced solid tumors.
Sponsor Eikon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants with Huntington’s Disease
Sponsor Skyhawk Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Two-arm, Double-blind, Double dummy, Parallel-group Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease
Sponsor Intas Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF).
Sponsor Puretech Lyt 100 Inc.
- Start (EU)
- Latest update
- Estimated end
Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases
Sponsor Tg Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Participants and Multiple-Ascending Doses and Proof-of-Concept in Participants with Cystic Fibrosis
Sponsor Recode Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer
Sponsor Gilead Sciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Novotech?
The 2026-10-09 snapshot links Novotech to 33 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Regulatory services, Investigator recruitment, among 19 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Novotech?
The most frequently recorded therapeutic areas are Immunology, Cardiology, Genetic and Congenital Disorders, Hepatology. Recorded phases include Phase 2, Phase 1, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Novotech conducted?
The linked trials record locations in 18 countries, including Spain, Germany, France, Poland, Italy. These are trial locations, not confirmed office locations or countries where Novotech delivered services.
What can this page tell me about Novotech's trial experience?
Browse 33 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 7 recorded name variants under Novotech. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Novotech
- Novotech (Australia) Pty Limited
- Novotech CRO
- Novotech Clinical Research (Cyprus) Limited
- Novotech Clinical Research (Romania) S.R.L.
- Novotech Laboratory Services (Shanghai) Co. Ltd.
- Novotech Laboratory Services (Taiwan) Co. Ltd.